Athira Pharma (NASDAQ:ATHA) versus OnKure Therapeutics (NASDAQ:OKUR) Head to Head Survey

OnKure Therapeutics (NASDAQ:OKUR) and Athira Pharma (NASDAQ:ATHA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, profitability, analyst recommendations and earnings.

Analyst Ratings

This is a summary of recent ratings and target prices for OnKure Therapeutics and Athira Pharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OnKure Therapeutics	1	2	1	0	2.00
Athira Pharma	1	0	0	0	1.00

OnKure Therapeutics presently has a consensus price target of $27.00, suggesting a potential upside of 508.11%. Athira Pharma has a consensus price target of $4.00, suggesting a potential downside of 51.34%. Given OnKure Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe OnKure Therapeutics is more favorable than Athira Pharma.

Insider and Institutional Ownership

91.0% of OnKure Therapeutics shares are held by institutional investors. Comparatively, 57.1% of Athira Pharma shares are held by institutional investors. 17.9% of OnKure Therapeutics shares are held by company insiders. Comparatively, 19.8% of Athira Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

OnKure Therapeutics has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500. Comparatively, Athira Pharma has a beta of 2.79, indicating that its stock price is 179% more volatile than the S&P 500.

Earnings and Valuation

This table compares OnKure Therapeutics and Athira Pharma”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OnKure Therapeutics	N/A	N/A	-$59.52 million	($4.33)	-1.03
Athira Pharma	N/A	N/A	-$96.94 million	($9.68)	-0.85

OnKure Therapeutics is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares OnKure Therapeutics and Athira Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OnKure Therapeutics	N/A	-61.02%	-55.99%
Athira Pharma	N/A	-107.06%	-89.89%

Summary

OnKure Therapeutics beats Athira Pharma on 8 of the 11 factors compared between the two stocks.

About OnKure Therapeutics

OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.

About Athira Pharma

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.